Bristol Myers Squibb, GSK and Merck are contributing drug ingredients as part of their deals with the White House but are ...

According to multiple recent market analyses, the global API market is experiencing steady growth. One comprehensive forecast projects the global active pharmaceutical ingredient market to expand from ...

HANGZHOU, ZHEJIANG, CHINA, January 16, 2026 /EINPresswire.com/ -- The pharmaceutical industry is undergoing a period of ...

SK Capital Partners have signed a definitive agreement to divest the Noramco API related assets in a sale to Siegfried (Zofingen Switzerland) -- The transaction is subject to customary closing ...

As supply chain vulnerabilities intensify and competition accelerates, the cost of this underutilization could risk India's competitive position.

North America: Largest market, powered by high drug consumption, strong regulatory frameworks, and advanced biotech manufacturing infrastructure. Asia Pacific: Fastest-growing, led by India's contract ...

AUSTIN, Texas and TOKYO, Oct. 3, 2025 /PRNewswire/ -- According to DataM Intelligence, the Active Pharmaceutical Ingredients Market Size reached US$ 238.7 Billion in 2024, up from US$ 224.7 Billion in ...

Halo Pharma, a CDMO, will become a stand-alone business as a result of the sale of the Noramco API and associated businesses ...

C2 Pharma, which concentrates on hard-to-make ingredients, has picked up a new supply of digoxin. The deal will give it two supplies of API for making the sometimes-difficult-to-get drug. The ...

Ajinomoto Bio-Pharma Services is taking full control of an API manufacturing facility in India as the CDMO continues to bulk up in a market that favors companies that can do it all. Ajinomoto ...

Ahead of Budget 2026, pharma industry pushes for API self-reliance and export competitiveness. As the Union Budget 2026-27 ...

India’s largest drug-maker Sun Pharmaceutical Industries posted a 16 per cent year-on-year (Y-o-Y) growth in its consolidated ...